Sirolimus for the prevention of in-stent restenosis in a coronary artery.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  New England Journal of Medicine

• Publication date

  2003-10-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMP038141PMID 14523135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003cited by this paper
• Coronary Restenosis After Sirolimus‐Eluting Stent Implantation: Morphological Description and Mechanistic Analysis From a Consecutive Series of Cases

  2003cited by this paper
• Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle.

  1999cited by this paper
• Rapamycin inhibits vascular smooth muscle cell migration.

  1996cited by this paper
• Rapamycin resistance tied to defective regulation of p27Kip1

  1996cited by this paper
• Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.

  1995cited by this paper

• Surface engineering at the nanoscale: A way forward to improve coronary stent efficacy

  2021cites this paper
• β-Blockers Reduced the Target Lesion Revascularization After Percutaneous Coronary Intervention Using an Everolimus-eluting Stent

  2021cites this paper
• LCK inhibitor attenuates atherosclerosis in ApoE-/- mice via regulating T cell differentiation and reverse cholesterol transport.

  2020cites this paper
• Combinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty ex vivo.

  2020cites this paper
• Design Parameters for Drug-Coated Balloons II

  2019cites this paper
• Drug-Coated Balloons

  2019cites this paper
• Ryanodine Receptor Structure and Function in Health and Disease.

  2018cites this paper
• Ryanodine receptor dysfunction in human disorders.

  2018cites this paper
• Membrane Protein Complexes: Structure and Function

  2018cites this paper
• In Vitro Diabetic-Hypertensive Cellular-Response Evaluation Model for In-Stent Restenosis

  2017cites this paper
• irolimus and Paclitaxel n Polymer-Based Drug-Eluting Stents imilar But Different

  2016cites this paper
• Biodegradable Polymers Influence the Effect of Atorvastatin on Human Coronary Artery Cells

  2016cites this paper
• mammalian target of rapamycin human arterial smooth muscle line (E47) through the Rapamycin inhibits fibronectin-induced migration of the

  2016cites this paper
• The Journal of Clinical Investigation

  2016cites this paper
• MicroRNAs and Endothelial (Dys) Function

  2016cites this paper
• Magnetic Nanoparticle-Mediated Targeting of Cell Therapy Reduces In-Stent Stenosis in Injured Arteries.

  2016cites this paper
• microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis.

  2015cites this paper
• Anti-inflammatory therapies for atherosclerosis

  2015cites this paper
• Optical coherence tomography surveillance following drug-eluting stent implantation.

  2015cites this paper
• Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

  2015cites this paper
• Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

  2015cites this paper
• Mammalian Target of Rapamycin Complex 2 (mTORC2) Coordinates Pulmonary Artery Smooth Muscle Cell Metabolism, Proliferation, and Survival in Pulmonary Arterial Hypertension

  2014cites this paper
• A selective microRNA-based strategy inhibits restenosis while preserving endothelial function.

  2014cites this paper
• miR-221/222 Compensates for Skp2-Mediated p27 Degradation and Is a Primary Target of Cell Cycle Regulation by Prostacyclin and cAMP

  2013cites this paper
• Oral everolimus inhibits intimal proliferation in injured carotid artery in rats

  2013cites this paper
• Targeted vascular drug delivery. A new day for an old way.

  2013cites this paper
• Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.

  2013cites this paper
• Possible Correlation of Sirolimus Plasma Concentration with Sinusoidal Obstructive Syndrome of the Liver in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

  2012cites this paper
• DES "club sandwich": a viable (if imperfect) option for recalcitrant restenosis.

  2011cites this paper
• Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.

  2011cites this paper
• Comparison of restenosis rate with sirolimus-eluting stent i n STEMI patients with and without diabetes at 6-month angiographic follow-up

  2011cites this paper
• Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase.

  2010cites this paper
• Vergleich der Effektivität und Sicherheit eines polymerfreien Sirolimus beschichteten mit einem polymertragenden Sirolimus beschichteten Stents

  2010cites this paper
• Drug-coated balloons for the prevention of vascular restenosis.

  2010cites this paper
• Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost.

  2010cites this paper
• Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment.

  2009cites this paper
• Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus

  2009cites this paper
• Role of vascular progenitor cells in cardiovascular disease.

  2009cites this paper
• Nanotechnology in Cardiology

  2009cites this paper
• [Drug-eluting stent-associated thrombosis: clinical relevance of impaired vessel-wall healing].

  2008cites this paper
• Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors

  2008cites this paper
• Induction of vascular atrophy as a novel approach to treating restenosis. A review.

  2008cites this paper
• Contribution of circulating vascular progenitors in lesion formation and vascular healing: lessons from animal models

  2008cites this paper
• Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.

  2008cites this paper
• Therapeutic Application of Bone Marrow-derived Progenitor Cells for Vascular Diseases: Magicbullets Having the Good Without the Bad?

  2007cites this paper
• Concurrent implantation of sirolimus‐ and paclitaxel‐eluting stents in the same vessel

  2007cites this paper
• Expanding mTOR signaling

  2007cites this paper
• Inactivation of vascular smooth muscle cells photosensitised by liposome-delivered Zn(II)-phthalocyanine.

  2006cites this paper
• Angioplasty for Renovascular Hypertension in Children: 20-Year Experience

  2006cites this paper
• Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different.

  2006cites this paper
• Comparisons of the Short-Term Angiographic Outcomes of Cypher and Taxus Stents Implanted in the Same Patient

  2006cites this paper
• "HEMORRAGIA INTRACRANEAL POST-TROMBOLISIS: DATOS DEL REGISTRO

  2006cites this paper
• LY303511 (2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms

  2005influential citation
• Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells

  2005cites this paper
• Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin.

  2005cites this paper
• Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1

  2005cites this paper
• In vitro study of drug loading on polymer-free oxide films of metallic implants.

  2005cites this paper
• Brachytherapy: here today, gone tomorrow?

  2005cites this paper
• The role of circulating precursors in vascular repair and lesion formation

  2005cites this paper
• Comparison of restenosis rates of two coronary stent systems with different active coating

  2005cites this paper
• Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide-stimulated human mononuclear cells and serum-stimulated aortic smooth muscle cells

  2005cites this paper
• Signaling to translational control pathways: diversity in gene regulation in inflammatory and vascular cells.

  2005cites this paper
• Current Treatment Strategies for Coronary Disease in Japan

  2005cites this paper
• Preclinical restenosis models and drug-eluting stents: still important, still much to learn.

  2004cites this paper
• Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

  2004cites this paper
• Upstream and downstream of mTOR.

  2004cites this paper
• Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.

  2004cites this paper
• Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs.

  2004cites this paper
• Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction.

  2004cites this paper
• Targeting the molecular target of rapamycin (mTOR)

  2004cites this paper
• Cardiovascular disease in diabetics: pharmacology and revascularization.

  2004influential citation
• Perivascular delivery of neomycin inhibits the activation of NF-κB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury

  2004cites this paper
• Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.

  2004cites this paper
• Wann sind Drug-eluting Stents als wirksam zu bezeichnen?

  2004cites this paper
• Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism.

  2004cites this paper
• [When are drug-eluting stents effective? A critical analysis of the presently available data].

  2004cites this paper
• Bone marrow – derived immune cells regulate vascular disease through a p 27 Kip 1-dependent mechanism

  2004cites this paper
• Cancer, type 2 diabetes, and ageing: news from flies and worms.

  2004cites this paper
• Sirolimus-Eluting Coronary Stents: Novel Devices for the Management of Coronary Artery Disease

  2004cites this paper
• Stent-based controlled release of intravascular angiostatin to limit plaque progression and in-stent restenosis.

  2004cites this paper
• Clinical Trials: Viewpoint

  2004cites this paper
• MORE POSITIVE NEWS ABOUT SIROLIMUS-ELUTING STENTS

  2004cites this paper
• Wann sind Drug-eluting Stents als wirksam zu bezeichnen?

  2004cites this paper
• Will Sirolimus-Eluting Stents Consign Bare Metal to History?

  2003cites this paper
• The Sheer Stress of Shear Stress: Responses of the Vascular Wall to a Haemodynamic Force

  2003cites this paper
• Drug-Eluting Stents for Off-Label Indications

  year unknowncites this paper
• BUCHBINDER TARgETED VASCULAR DRUg DELIVERy

  year unknowncites this paper
• International Journal of Nanomedicine Dovepress Pretreatment with Intraluminal Rapamycin Nanoparticle Perfusion Inhibits Neointimal Hyperplasia in a Rabbit Vein Graft Model

  year unknowncites this paper